Exousia Bio, Inc. (formerly LAMY) has officially shifted its business focus from a financial education platform to clinical-stage biotechnology, centered on developing exosome-based therapeutics for oncology, following the acquisition of Exousia AI. The company reported a net loss of $50,897 for the nine months ended February 28, 2026, compared to a net income of $80,659 for the same period in the prior year. As of February 28, 2026, the company had no cash and cash equivalents and a working capital deficit of $261,023, raising substantial doubt about its ability to continue as a going concern. Significant operational expenses were incurred in research and development ($161,426) and professional fees ($31,350) during the nine months ended February 28, 2026, related to the acquisition and new business plan. A $250,000 convertible promissory note issued in January 2026 matured on March 26, 2026, and the company lacks the cash to repay it, potentially leading to significant shareholder dilution. The company's name was officially changed from LAMY to Exousia Bio, Inc. on January 31, 2026.